alexa The Src And C-Kit Kinase Inhibitor Dasatinib Enhances P53-mediated Targeting Of Human Acute Myeloid Leukemia Stem Cell By Chemotherapeutic Agents
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

International Conference on Hematology & Blood Disorders
September 23-25, 2013 DoubleTree by Hilton Hotel Raleigh-Durham Airport at RTP, NC, USA

Cedric Dos Santos
Accepted Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864.S1.004
The SRC Family Kinases (SFKs) and the receptor tyrosine kinase c-Kit, are activated in human acute myeloid leukemia (AML) cells. We show here that the SFKs LYN, HCK or FGR are overexpressed and activated in AML progenitor cells. Treatment with the SFK and c-KIT inhibitor dasatinib selectively inhibits human AML stem/progenitor cell growth in vitro. Importantly, dasatinib markedly increases the elimination of AML stem cells capable of engrafting immunodeficient mice by chemotherapeutic agents. In vivo dasatinib treatment enhances chemotherapy induced targeting of primary murine AML stem cells capable of regenerating leukemia in secondary recipients. Our studies suggest that enhanced targeting of AML cells by the combination of dasatinib with daunorubicin (DNR) may be related to inhibition of AKT mediated HDM2 phosphorylation, resulting in enhanced p53 activity in AML cells. Combined treatment using dasatinib and chemotherapy provides a novel approach to increase p53 activity and enhance targeting of AML stem cells.
Cedric Dos Santos received his Bachelors and Masters degrees from University Paul Sabatier, Toulouse III, France, and completed his Ph.D. from the same university in December 2008. He has a long time interest in studying deregulated signaling pathways and has published several high impact publications in 2008 in Blood , like ?A critical role of Lyn in Acute Myeloid Leukemia ? and in 2009 in Leukemia . He joined Ravi Bhatia laboratory, City of Hope, Duarte, CA, as a post-doctoral fellow in February 2009. In one of his work, he discovered a new original and efficient therapeutic avenue for the treatment of AML, and this study is published in the journal Blood last month. In August 2013, he accepted a faculty position at the University of Pennsylvania in the group of Martin Carroll and Gwenn Danet-Desnoyers.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version